Skip to main content
All lobbying filings

Tiber Creek Group

Tiber Creek Group filed a Q3 report for Acadia Pharmaceuticals, Inc. on October 19, 2025, reporting $80,000 in lobbying income.

Lobbying for Acadia Pharmaceuticals, Inc. · Biopharmaceutical company.

As filed: TIBER CREEK GROUP for ACADIA PHARMACEUTICALS, INC.

All filings by Tiber Creek Group · Everything Acadia Pharmaceuticals, Inc. has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 19, 2025
Income
$80,000
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.

Taxation/Internal Revenue Code

Issues related to the orphan drug tax credit.

 Bills named in this filing 2
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • S. 932
    Give Kids a Chance Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem